Moderna flu vaccine approved by FDA

Moderna announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved its new influenza vaccine. The approval comes after the agency had previously rejected the company’s application for review only briefly, a decision that was reversed following a subsequent submission by Moderna.

The vaccine, designed to protect against the most common strains of seasonal flu, follows Moderna’s ongoing efforts to expand its portfolio beyond COVID‑19 products. The FDA’s approval process included a review of the vaccine’s safety and efficacy data, which met the agency’s standards for a new influenza immunization. The company stated that the vaccine will be available to the public shortly after the approval is finalized.

With the approval, Moderna adds a new seasonal flu option to the U.S. market, potentially increasing the range of vaccines available to healthcare providers and patients. The agency’s decision is expected to influence flu vaccination strategies for the upcoming season.